ETOPOSIDE (VP-16-213) IN MALIGNANT BRAIN-TUMORS - A PHASE-II STUDY

被引：89

作者：

TIRELLI, U

DINCALCI, M

CANETTA, R

TUMOLO, S

FRANCHIN, G

VERONESI, A

GALLIGIONI, E

TROVO, MG

ROSSI, C

GRIGOLETTO, E

机构：

[1] MARIO NEGRI INST PHARMACOL RES,I-20157 MILAN,ITALY

[2] BRISTOL MYERS CO,DIV PHARMACEUT RES & DEV,NEW YORK,NY

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1984年 / 2卷 / 05期

关键词：

D O I：

10.1200/JCO.1984.2.5.432

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：432 / 437

页数：6

共 29 条

[21]

MAROUN JA, 1982, P AM SOC CLIN ONCOL, V1, P140

[22]

RADICE PA, 1979, CANCER TREAT REP, V63, P1231

[23]

SKLANSKY BD, 1974, CANCER-AM CANCER SOC, V33, P460, DOI 10.1002/1097-0142(197402)33:2<460::AID-CNCR2820330222>3.0.CO

[24]

2-5

[25]

SPREMULLI E, 1980, CANCER TREAT REP, V64, P147

[26] ACTIVITY OF A NEW GLYCOSIDIC LIGNAN DERIVATIVE (VP 16-213) RELATED TO PODOPHYLLOTOXIN IN EXPERIMENTAL TUMORS [J].

STAHELIN, H .

EUROPEAN JOURNAL OF CANCER, 1973, 9 (03) :215-221

[27]

STEWART DJ, 1983, P AM ASSOC CANC RES, V24, P133

[28]

SWEET DL, 1979, CANCER TREAT REP, V63, P1707

[29]

Yamamoto H, 1979, Acta Neurochir Suppl (Wien), V28, P616

← 1 2 3 →